Discontinuing BTK Inhibitors for CLL

(STOP-CLL-DCT Trial)

This trial investigates whether patients with chronic lymphocytic leukemia (CLL) can discontinue Bruton tyrosine kinase inhibitors (BTKi) after at least two years of remission. Researchers aim to determine how long patients remain disease-free and whether their quality of life improves without the medication. The study also examines whether the body's immune function improves and the risk of infections decreases after stopping the therapy. This trial may suit those with CLL or small lymphocytic lymphoma (SLL) who have been in remission for two years on BTKi treatment. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to significant findings.

The trial specifically involves stopping Bruton tyrosine kinase inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL) who have been in remission for at least two years. It does not mention stopping other medications, so you should discuss your current medications with the study team.

Previous studies have shown that Bruton tyrosine kinase inhibitors (BTKi) are generally safe for patients with chronic lymphocytic leukemia (CLL). Research indicates that these treatments often have manageable side effects. For example, one study found that patients using BTKi like ibrutinib or acalabrutinib faced a lower risk of severe side effects compared to some other treatments.

Real-world data supports these findings. In a large study, about 30.9% of patients stopped BTKi therapy due to side effects, but many of these side effects were mild and didn't require long-term treatment changes. Patients often felt better after stopping the therapy, suggesting the medication caused the side effects.

Bruton tyrosine kinase inhibitors (BTKi) are unique because they offer a targeted approach to treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Unlike traditional chemotherapy, which attacks rapidly dividing cells indiscriminately, BTK inhibitors specifically block signals that help cancer cells survive and thrive. This targeted action can lead to fewer side effects and improved quality of life for patients. Researchers are excited because these inhibitors have shown promise in maintaining remission in patients who've already responded well to treatment, potentially allowing them to discontinue therapy while keeping the disease under control.

Studies have shown that Bruton tyrosine kinase inhibitors (BTKi) effectively treat chronic lymphocytic leukemia (CLL). For example, one study found a low risk of disease progression after starting BTKi treatment. Another study reported that patients who stopped BTKi due to side effects experienced quick relief. Research indicates that BTKi treatment is generally well-tolerated and beneficial for CLL patients. Overall, BTKi serves as a reliable option for managing CLL, with many patients experiencing extended periods without disease progression. This trial will focus on patients with CLL or small lymphocytic lymphoma (SLL) who have received covalent BTKi for at least two years and have achieved clinical remission.³⁶⁷⁸⁹